A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
10.9758/cpn.2021.19.1.160
- Author:
Kyung Ho LEE
1
;
Won-Myong BAHK
;
Soo-Jung LEE
;
Alessandro SERRETTI
;
Chi-Un PAE
Author Information
1. Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:Brief Report
- From:Clinical Psychopharmacology and Neuroscience
2021;19(1):160-165
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.
Methods:Nine patients were prescribed NeuropharmagenⓇ for selection of antidepressants for individual patient and their clinical outcomes were followed.
Results:After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.
Conclusion:Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
